Gene-marked Autologous Hematopoietic Stem Cell Transplantation of Autoimmune Disease
Overview
Overview
Journal
J Clin Immunol
Publisher
Springer
Specialty
Allergy & Immunology
Date
2000 May 8
PMID
10798601
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.
References
1.
Hanenberg H, Xiao X, Dilloo D, Hashino K, Kato I, Williams D
. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 1996; 2(8):876-82.
DOI: 10.1038/nm0896-876.
View
2.
LEVY J, Muldoon R, Zolotukhin S, Link Jr C
. Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells. Nat Biotechnol. 1996; 14(5):610-4.
DOI: 10.1038/nbt0596-610.
View
3.
Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V
. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1998; 20(8):631-8.
DOI: 10.1038/sj.bmt.1700944.
View
4.
Miller A
. Retroviral vectors. Curr Top Microbiol Immunol. 1992; 158:1-24.
DOI: 10.1007/978-3-642-75608-5_1.
View
5.
Vassilopoulos D, Kovacs B, Tsokos G
. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol. 1995; 155(4):2269-81.
View